目的 探討振源膠囊聯(lián)合琥珀酸美托洛爾緩釋片治療冠心病心絞痛的臨床療效。方法 選取2019年4月—2020年10月南陽市中心醫(yī)院收治的85例冠心病心絞痛患者，按照隨機數(shù)字表法將85例患者分為對照組（42例）和治療組（43例）。對照組口服琥珀酸美托洛爾緩釋片，1片/次，1次/d。治療組在對照組治療的基礎(chǔ)上口服振源膠囊，0.5 g/次，3次/d。兩組患者連續(xù)治療1個月?？疾靸山M心絞痛、心電圖的療效，并比較兩組患者的心絞痛發(fā)作次數(shù)、每次持續(xù)時間、疼痛程度和血清因子水平。結(jié)果 治療后，治療組的心絞痛總有效率（93.02%）高于對照組（76.19%）（P<0.05）。治療后，治療組的心電圖總有效率（81.40%）高于對照組（61.90%）（P<0.05）。治療后，兩組的心絞痛發(fā)作次數(shù)、每次持續(xù)時間、視覺模擬評分法（VAS）評分明顯降低（P<0.05），且治療組發(fā)作次數(shù)、每次持續(xù)時間、VAS評分降低的更多（P<0.05）。治療后，兩組的丙二醛（MDA）、脊髓內(nèi)髓過氧化物酶（MPO）水平顯著降低，超氧化物歧化酶（SOD）水平顯著升高（P<0.05）；治療后，治療組的MDA、MPO水平比對照組低，SOD水平比對照組高（P<0.05）。結(jié)論 振源膠囊聯(lián)合琥珀酸美托洛爾緩釋片可提高冠心病心絞痛的臨床療效，有效減輕心絞痛癥狀，減輕氧化反應(yīng)。

Objective To investigate the clinical effect of Zhenyuan Capsules combined with Metoprolol Succinate Sustained-release Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (85 cases) with angina pectoris of coronary heart disease in Nanyang Central Hospital from April 2019 to October 2020 were randomly divided into the control group (42 cases) and the treatment group (43 cases). Patients in the control group were po administered with Metoprolol Succinate Sustained-release Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Zhenyuan Capsules on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the curative effect of angina pectoris and the ECG curative effect were evaluated, and the frequency and duration of angina pectoris, the degree of pain and the level of serum factors in two groups were compared. Results After treatment, the total effective rate of angina pectoris in the treatment group (93.02%) was higher than that in the control group (76.19%) (P<0.05). After treatment, the ECG curative effect in the treatment group (81.40%) was higher than that in the control group (61.90%) (P<0.05). After treatment, the frequency and duration of angina pectoris and the VAS score of two groups were significantly decreased (P<0.05), and the frequency and duration of angina pectoris and the VAS score of the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of MDA and MPO in two groups were significantly decreased, but the level of SOD in two groups was significantly increased (P<0.05). After treatment, the levels of MDA and MPO in the treatment group were lower than those in the control group, but the level of SOD in the treatment group was higher than that in the control group (P<0.05). Conclusion Zhenyuan Capsules combined with Metoprolol Succinate Sustained-release Tablets can improve the clinical efficacy of angina pectoris, reduce the symptoms and oxidation reaction.

R972

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建項目（LHGJ20191164）